Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
<strong>Background</strong> Disease caused by the capsular group B meningococcus (MenB) is the leading cause of infectious death in UK infants. A novel adenovirus-based vaccine encoding the MenB factor H binding protein (fHbp) with an N-terminal dual signal sequence induces high titres o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2022
|
| _version_ | 1797107174099386368 |
|---|---|
| author | Sheerin, D Dold, C Silva-Reyes, L Linder, A Pollard, AJ Rollier, CS |
| author_facet | Sheerin, D Dold, C Silva-Reyes, L Linder, A Pollard, AJ Rollier, CS |
| author_sort | Sheerin, D |
| collection | OXFORD |
| description | <strong>Background</strong>
Disease caused by the capsular group B meningococcus (MenB) is the leading cause of infectious death in UK infants. A novel adenovirus-based vaccine encoding the MenB factor H binding protein (fHbp) with an N-terminal dual signal sequence induces high titres of protective antibody after a single dose in mice. A panel of N-terminal signal sequence variants were created to assess the contribution of components of this sequence to transgene expression kinetics of the encoded antigen from mammalian cells and the resultant effect on immunogenicity of fHbp.
<br>
<strong>Results</strong>
The full-length signal sequence (FL SS) resulted in superior early antigen expression compared with the panel of variants, as measured by flow cytometry and confocal imaging, and supported higher bactericidal antibody levels against the expressed antigen in mouse sera < 6 weeks post-immunisation than the licensed four component MenB vaccine. The FL SS also significantly increased antigen-specific T cell responses against other adenovirus-encoded bacterial antigens in mice.
<br>
<strong>Conclusions</strong>
These findings demonstrate that the FL SS enhances immunogenicity of the encoded antigen, supporting its inclusion in other viral vectored bacterial antigen transgenes. |
| first_indexed | 2024-03-07T07:12:14Z |
| format | Journal article |
| id | oxford-uuid:69246fd5-2c73-4fa3-b7ea-aeb4097c9756 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:12:14Z |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:69246fd5-2c73-4fa3-b7ea-aeb4097c97562022-07-04T14:57:25ZInclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcusJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:69246fd5-2c73-4fa3-b7ea-aeb4097c9756EnglishSymplectic ElementsBioMed Central2022Sheerin, DDold, CSilva-Reyes, LLinder, APollard, AJRollier, CS<strong>Background</strong> Disease caused by the capsular group B meningococcus (MenB) is the leading cause of infectious death in UK infants. A novel adenovirus-based vaccine encoding the MenB factor H binding protein (fHbp) with an N-terminal dual signal sequence induces high titres of protective antibody after a single dose in mice. A panel of N-terminal signal sequence variants were created to assess the contribution of components of this sequence to transgene expression kinetics of the encoded antigen from mammalian cells and the resultant effect on immunogenicity of fHbp. <br> <strong>Results</strong> The full-length signal sequence (FL SS) resulted in superior early antigen expression compared with the panel of variants, as measured by flow cytometry and confocal imaging, and supported higher bactericidal antibody levels against the expressed antigen in mouse sera < 6 weeks post-immunisation than the licensed four component MenB vaccine. The FL SS also significantly increased antigen-specific T cell responses against other adenovirus-encoded bacterial antigens in mice. <br> <strong>Conclusions</strong> These findings demonstrate that the FL SS enhances immunogenicity of the encoded antigen, supporting its inclusion in other viral vectored bacterial antigen transgenes. |
| spellingShingle | Sheerin, D Dold, C Silva-Reyes, L Linder, A Pollard, AJ Rollier, CS Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus |
| title | Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus |
| title_full | Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus |
| title_fullStr | Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus |
| title_full_unstemmed | Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus |
| title_short | Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus |
| title_sort | inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group b meningococcus |
| work_keys_str_mv | AT sheerind inclusionofadualsignalsequenceenhancestheimmunogenicityofanovelviralvectoredvaccineagainstthecapsulargroupbmeningococcus AT doldc inclusionofadualsignalsequenceenhancestheimmunogenicityofanovelviralvectoredvaccineagainstthecapsulargroupbmeningococcus AT silvareyesl inclusionofadualsignalsequenceenhancestheimmunogenicityofanovelviralvectoredvaccineagainstthecapsulargroupbmeningococcus AT lindera inclusionofadualsignalsequenceenhancestheimmunogenicityofanovelviralvectoredvaccineagainstthecapsulargroupbmeningococcus AT pollardaj inclusionofadualsignalsequenceenhancestheimmunogenicityofanovelviralvectoredvaccineagainstthecapsulargroupbmeningococcus AT rolliercs inclusionofadualsignalsequenceenhancestheimmunogenicityofanovelviralvectoredvaccineagainstthecapsulargroupbmeningococcus |